FDAsafety guidance72% confidence
FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq for use in matched donor hematopoietic stem cell transplantation for adults with hematologic malignancies
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to AstraZeneca.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Hematology · CD123-targeted therapy
- Sub-indication
- General
Related signal: AstraZeneca initiates Phase I/II trial of AZD9829 for CD123+ hematological malignancies